3Wood GC,Hanes SD,Croce MA,et al.comparison of ampicillin-sulbctam and imipenem-cilastatin for the treatment of acintobacter ventilator-associated pneumonia[J].Clin Infect Dis,2002,34;1425-1430
2Bergogne-Berezin E. Guideline on antimicrobial chemotherapy for prevention and treatment of infections in the ICU. J Chemother, 2001,1: 134-149.
3Goossens H. MYSTIC program: summary of European data from 1997 to 2000. Diagn Microbiol Infect Dis, 2001, 41: 183-189.
4Leblebicioglu H, Gunaydin M, Esen S, et al. Surveillance of antimicrobial resistance in gram-negative isolates from ICU in Turkey:analysis of data from the last 5 years. J Chemother, 2002, 14:140-146.
5Karlowsky JA, Kelly LJ, Thornsberry C , et al. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000:TRUST and TSN data for the United States. J Autimicrob Agents , 2002,19: 21-31.
6National Committee for Clinical Laboratory Standards. 2002. Performance standards for antimicrobial susceptibility testing. Approved standard M100-S12. National Committee for Clinical Laboratory Standards,Wayne, Pa.2002,1.
7Chanawong A. M' Zali FH, Heritage J, et al. Three cefotaximases,CTX-M-9, CTX-M-13, CTX-M-14, among Enterobacteriaceae in the People's Republic of China. Antimicrob Agents Chemother, 2002, 46:630-637.
9Villers D;Espaze E;Coste-Burel M.Nosocomial Acinetobacter baumannii infections:microbiological and clinical epidemiology,1998.
10Koeleman JGM;Parlevliet GA;Dijkshoorn L.Nosocomial outbreak of multi-resistant Acinetbacter baumannⅡ on a surgical ward:epidemiology and risk factors for acquisition[J],1997.
